Hemostasis Today

May, 2026
May 2026
M T W T F S S
 123
45678910
11121314151617
18192021222324
25262728293031
Francisco Chacón-Lozsán: Anticoagulation Strategies for Complex ICU Patients
May 28, 2026, 13:16

Francisco Chacón-Lozsán: Anticoagulation Strategies for Complex ICU Patients

Francisco Chacón-Lozsán, Fellow at World Extreme Medicine, Member of European Society of Intensive Care Medicine (ESICM) and American College of Cardiology, shared a post on LinkedIn about a recent article by Mark A. Creager et al, published in Circulation, adding:

“Anticoagulation in the ICU is not one protocol.

It is a daily balance between thrombosis, bleeding, renal clearance, procedure timing, and the reason for anticoagulation.

Recent PubMed indexed guidance reinforces that critically ill patients need systematic VTE prophylaxis unless bleeding risk is prohibitive. (Bounes et al., 2024; Arabi and Mehta, 2025)

But dose is context.

Standard ICU prophylaxis is often enoxaparin 40 mg once daily or UFH 5000 IU every 8 to 12 hours.

In obesity, fixed low dosing may underdose patients, reflecting the need for higher or weight adjusted prophylaxis in selected patients. (Arcelus et al., 2024)

In AKI or severe CKD, UFH is often safer than LMWH because accumulation is less problematic and reversal is easier.

Therapeutic anticoagulation is a different question.

AF in the ICU requires stroke risk, bleeding risk, rhythm duration, procedures, renal function, and enteral absorption assessment.

The 2023 ACC/AHA/ACCP/HRS AF guideline supports DOACs over warfarin for most non valvular AF, but not for mechanical valves or moderate to severe rheumatic mitral stenosis. (Joglar et al., 2023)

PE in shock is not ‘just anticoagulation.’

It is anticoagulation plus reperfusion assessment.

The 2026 AHA/ACC multisociety PE guideline focuses on risk stratification, anticoagulation, catheter based therapy, thrombolysis, surgical embolectomy, and IVC filters when anticoagulation is impossible. (AHA/ACC/ACCP/ACEP/CHEST/SCAI/SHM/SIR/SVM Writing Committee, 2026)

Mechanical valves remain warfarin territory.

DOACs are not substitutes.

Bridging decisions must consider valve type, position, prior stroke, AF, LV dysfunction, and bleeding risk.

Liver failure is not ‘auto anticoagulated.’

Cirrhosis creates rebalanced but fragile hemostasis.

Hospitalized cirrhotic patients can thrombose and may still need prophylaxis or treatment when bleeding risk is controlled. (Roark et al., 2024)

Recent stroke, major surgery, ACS, elderly frailty, thrombocytopenia, and renal dysfunction all change the equation.

Mechanical prophylaxis may be useful when pharmacological prophylaxis is temporarily unsafe, and a 2024 meta analysis supports intermittent pneumatic compression as an option in surgical patients, especially when bleeding risk limits anticoagulants. (Kim et al., 2024)

References

Title: 2026 AHA/ACC/ACCP/ACEP/CHEST/SCAI/SHM/SIR/SVM/SVN Guideline for the Evaluation and Management of Acute Pulmonary Embolism in Adults: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines

Authors: Mark A. Creager, Geoffrey D. Barnes, Jay Giri, Debabrata Mukherjee, William Schuyler Jones, Allison E. Burnett, Teresa Carman, Ana I. Casanegra, Lana A. Castellucci, Sherrell M. Clark, Mary Cushman, Kerstin de Wit, Jennifer M. Eaves, Margaret C. Fang, Joshua B. Goldberg, Stanislav Henkin, Hillary Johnston-Cox, Sabeeda Kadavath, Daniella Kadian-Dodov, William Brent Keeling, Andrew J.P. Klein, Jun Li, Michael C. McDaniel, Lisa K. Moores, Gregory Piazza, Karen S. Prenger, Steven C. Pugliese, Mona Ranade, Rachel P. Rosovsky, Farla Russo, Eric A. Secemsky, Akhilesh K. Sista, Leben Tefera, Ido Weinberg, Lauren M. Westafer, Michael N. Young

Francisco Chacón-Lozsán: Anticoagulation Strategies for Complex ICU Patients

Stay updated on all scientific advances with Hemostasis Today.